logo

For the Inventor, By the Inventor

Takarazuka, Japan

Masaji Ishiguro

This inventor holds 13 USPTO granted patents, primarily in Antibacterial Compounds. Top assignees: Suntory Limited, Nippon Soda Co., Ltd., Daiichi Suntory Pharma Co., Ltd.. Active years: 1991-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masaji Ishiguro. Retrieved from https://idiyas.com/inventor/masaji-ishiguro

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13

% Patents Active = 92.3

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 38(Granted Patents)


Location History:

  • Mishima, JP (1991)
  • Osaka, JP (1991 - 1992)
  • Hyogo-ken, JP (1998)
  • Takarazuka, JP (1996 - 2012)

Company Filing History:

goldMedal11 out of 439 
 
Suntory Limited
 patents
silverMedal2 out of 517 
 
Nippon Soda Co., Ltd.
 patents
bronzeMedal1 out of 23 
 
Daiichi Suntory Pharma Co., Ltd.
 patents
4. 1 out of 1,329 
 
Japan Science and Technology Agency
 patents
5. 1 out of 873 
 
Kyoto University
 patents
6. 1 out of 5 
 
Nagoya City University
 patents
where one patent can have more than one assignee

Years Active: 1991-2012

Loading Chart...
Areas of Expertise:
G-Protein-Conjugated Receptor Agonist
Azetidinone Derivatives
Carbapenem Derivatives
Optically Active Compounds
Antimicrobial Agents
Desilylating Compounds
Penem Compounds
Synthesis Processes
Antibacterial Agents
13 patents (USPTO):Explore Patents
1. 8318781 - G-protein-conjugated receptor agonist (2012-11-27),
2. 6867297 - Process for synthesizing 4-substituted azetidinone derivatives (2005-03-15),
3. 6051569 - 1'S, 5R, 6R-carbapenem derivatives and antimicrobial agents comprising (2000-04-18),
4. 6049009 - Production method of optically active trans-vinylsulfide alcohol (2000-04-11),
5. 5885981 - Antibacterial penem esters derivatives (1999-03-23),
6. 5830889 - Antibacterial penem esters derivatives (1998-11-03),
7. 5821362 - Method of desilylating silylether compounds (1998-10-13),
8. 5703068 - Penem compounds (1997-12-30),
9. 5506225 - Antibacterial penem compounds (1996-04-09),
10. 5116832 - Penem derivatives production and use thereof (1992-05-26),
11. 5026844 - Process for the preparation of 4-acyloxy-2-azetidinone derivatives (1991-06-25),
12. 4997829 - Penem compounds, and use thereof (1991-03-05),
13. 4985575 - Process for preparing optically active tetrahydro-2-furoic acid (1991-01-15),

Title: Masaji Ishiguro: Innovator in Pharmaceutical Chemistry

Introduction

Masaji Ishiguro is a prominent inventor based in Takarazuka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 13 patents. His work focuses on developing novel compounds with therapeutic applications.

Latest Patents

One of his latest patents involves a G-protein-conjugated receptor agonist. This patent discloses a novel aralkyl carboxylic acid compound that exhibits agonistic activity on GPR-120 and/or GPR-40. This compound is particularly useful as an appetite regulator, an anti-obesity agent, and a therapeutic agent for various conditions, including diabetes and metabolic syndrome. Another recent patent details a process for synthesizing 4-substituted azetidinone derivatives, which involves reacting specific azetidinone derivatives with ester compounds in the presence of zinc and copper compounds.

Career Highlights

Throughout his career, Masaji Ishiguro has worked with notable companies such as Suntory Limited and Nippon Soda Co., Ltd. His innovative approaches have led to advancements in drug development and therapeutic solutions.

Collaborations

Masaji Ishiguro has collaborated with esteemed colleagues, including Takashi Nakatsuka and Hiromitsu Iwata. These partnerships have further enhanced his research and development efforts.

Conclusion

Masaji Ishiguro's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a leading inventor in the field. His work continues to impact the development of therapeutic agents for various health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…